In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.
Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERTâ„¢ platform. In return, ...
Using a pioneering artificial intelligence platform, Flinders University researchers have assessed whether a cardiac AI tool ...
GenAI-powered solution delivers clinical study reports in minutes with 30%–50% faster turnarounds, 90% ICH-E3-aligned ...
The evolution of protocol management within eQMS represents another significant advance in clinical trials. Version control ...
Dr. Mrinal M Gounder emphasizes the complexity of breast cancer and the necessity for unique treatments for its many variants. The Jeevan project aims to overcome challenges in patient participation ...
CARY, NORTH CAROLINA / ACCESS Newswire / January 30, 2025 / Yunu, a leading provider of clinical trial imaging workflow and data management solutions, is pleased to announce its partnership with ...
CARY, NORTH CAROLINA / ACCESS Newswire / January 30, 2025 / Yunu, a leading provider of clinical trial imaging workflow and data management solutions, is pleased to announce its partnership with WCG, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results